Fracture risk is reduced in postmenopausal women who initiate hormone therapy (HT), especially in those at greatest genetic risk of fracture and low bone mineral density (BMD), a recent study found. The study included 9,922 genotyped white postmenopausal women aged 50 to 79 years from the Women’s Health Initiative HT randomized trials and 40 US clinical centers. 2 weighted genetic risk scores (GRSs) were developed based on 16 fracture-associated variants (Fx-GRS) and 50 BMD variants (BMD-GRS). Researchers found:
- Both GRSs were associated with fracture risk (HR per 1-unit increment in GRS, 1.04 for FX-GRS and 1.03 for BMD-GRS).
- There was no evidence for multiplicative interaction for either of the GRSs.
- There was however, a significant additive interaction, where the highest quartile of both GRSs and randomization to placebo have excess fracture risk.
Wang Y, Wactawski-Wende J, Sucheston-Campbell LE, et al. Gene-hormone therapy interaction and fracture risk in postmenopausal women. [Published online ahead of print March 6, 2017]. J Clin Endocrinol Metab. doi:10.1210/jc.2016-2936.
This Week's Must Reads
Must Reads in Menopause
Menopause Symptom Burden and Chronic Pain, Menopause; ePub 2019 Mar 4; Gibson, et al
Trends in Menopausal Hormone Therapy, Menopause; ePub 2018 Dec 21; Crawford, et al
Chronic Disease Risk with Vaginal Estrogen Use, Menopause; ePub 2018 Dec 17; Bhupathiraju, et al
Sleep Disturbance After Surgical Menopause, Menopause; ePub 2018 Nov 12; Cho, Kim, et al
Cardiac Autonomic Function in Midlife Women, Menopause; ePub 2018 Jun 18; Fu, et al